Chugai gets rights to develop Roche's MetMab and lebrikizumab in Japan

5 September 2011

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519)l has entered into license agreements with its majority shareholder Roche (ROG: SIX) of Switzerland covering humanized anti-Met antibody MetMAb, for non-small cell lung cancer (NSCLC), and humanized anti-interleukin (IL)-13 antibody lebrikizumab for bronchial asthma.

Both products are currently being developed by Roche utilizing the Personalized Healthcare (PHC) approach and have also entered Phase I clinical studies in the Japanese population. Under the terms of the deal, Chugai gains rights for the development and marketing of these compounds in Japan, and will make undisclosed milestone payments to Roche.

Current development status

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK